Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates

ALT shares drop over 20% after updated pemvidutide week 48 data; see FDA's stance on non-invasive fibrosis tests. Click here ...

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's pemvidutide shows strong Phase IIb results for MASH, promising Phase III prospects. Read here for more analysis ...
BioSpace

Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.

FDA approves Novo Nordisk's Wegovy(R) pill, the first and only oral GLP-1 for weight loss in adults

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy (R) pill, the first oral GLP-1 medicine for obesity in the US. (3) Wegovy (R) pill is used ...
Medindia

FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy® pill, the first oral GLP-1 medicine for obesity in the US.3 Wegovy® pill is used with a ...